Patient Focus
  Board of Directors
  Corporate Policies/Governance
  Contact DURECT
  Driving Directions

According to the CDC, cardiovascular disease, cancer, diabetes and other chronic diseases claimed the lives of more than 3.2 million Americans in 2005.

DURECT is a biopharmaceutical company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, CNS disorders, acute organ injury and metabolic diseases. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. Late stage development programs of this nature include POSIDUR and REMOXY. DURECT’s Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 clinical testing. DUR-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival.

The statements within the DURECT Corporation website, and affiliated websites, relating to DURECT's products in development, technology attributes or capabilities, product development plans, development timelines, expected product or technology benefits or potential product markets involve risks and uncertainties that could cause actual results to differ materially from those in such forward looking statements. Potential risks and uncertainties include, but are not limited to, our ability to develop and commercialize our products, our ability to complete successful clinical trials, our ability to obtain product approvals from regulatory agencies, marketplace acceptance of our products, our ability to successfully manufacture our products, our reliance on sole or limited suppliers, our ability to obtain adequate reimbursement from third-party payors and the introduction of competitive products by other companies, our ability to gain access to proprietary technology and drugs, our ability to enter into development or commercialization agreements with other life sciences companies, our ability to manage our growth and costs and relationships with third parties and finance our activities and operations. Further information regarding these and other risks is included in the company's S-1 registration statement, quarterly reports on Form 10-Q and annual report on Form 10-K, as filed with the SEC. Copies of these documents are available on request from the Investor Relations Department of DURECT.

NOTE: POSIMIR™, SABER®, TRANSDUR®, ORADUR®, ELADUR™, DURIN®, MICRODUR™, ALZET® and LACTEL® are trademarks of DURECT Corporation. Other trademarks referred to belong to their respective owners.

 © 2000-2015 DURECT Corporation
Last updated: November 30, 2015
Search     Contact     Site Index     Legal Notice     Privacy Policy